KIMS shares rose 1.31% to ₹774.10 following the announcement that the company's board is scheduled to meet on Saturday, June 13, 2026, to consider raising funds through different instruments in one or more tranches. The proposed fund raise may involve equity shares, fully convertible warrants, convertible or non-convertible securities, or a combination thereof through permissible modes, including a preferential issue on a private placement basis or any other approved route. This development comes as the healthcare provider continues to strengthen its balance sheet through strategic fundraising initiatives.
The company's net profit declined 58.25% to ₹42.5 crore in Q4 FY26 compared to ₹101.8 crore in Q4 FY25, though revenue from operations increased 34.85% YoY to ₹1,074.6 crore in the same quarter. For the full year ended March 2026, net profit declined 37.22% to ₹241.40 crore against ₹384.50 crore in the previous year, while revenue increased 28.65% to ₹3,904.60 crore. The company's operating margins compressed to 19.22% in Q3 FY26 from 24.85% in the previous quarter, reflecting operational challenges from new units and expansion activities.
The company's robust expansion and rising occupancies are positioning it for strong earnings acceleration, according to Moneycontrol reports. KIMS operates 25 hospitals across Andhra Pradesh, Telangana, Karnataka, Odisha, Tamil Nadu and Central India, with recent expansion including a new hospital in Chennai. The company has also secured 2 acres of land in Amravati for a proposed multi-speciality hospital offering comprehensive tertiary and quaternary care across cardiology, oncology, neurosciences, and other specialties, addressing regional healthcare infrastructure needs.
Margin recovery is in sight for KIMS, as reported by Moneycontrol. The company's operational improvements and strategic focus are expected to contribute to improved profitability metrics in the coming periods, supporting the positive outlook for the healthcare provider. However, recent financial results show EBITDA margins declining to 19.94% in Q3 FY26 from 24.24% in the previous quarter, indicating ongoing challenges in operational efficiency amid expansion activities.
